123 related articles for article (PubMed ID: 7392026)
1. Aporphines. 30. (-)-N(2-chloroethyl)-10,11-dihydroxynor-aporphine (chloroethylnorapomorphine), a novel irreversible dopamine receptor antagonist.
Neumeyer JL; Law SJ; Baldessarini RJ; Kula NS
J Med Chem; 1980 Jun; 23(6):594-5. PubMed ID: 7392026
[No Abstract] [Full Text] [Related]
2. Chloroethylnorapomorphine, a proposed long-acting dopamine antagonist: interactions with dopamine receptors of mammalian forebrain in vitro.
Baldessarini RJ; Kula NS; Arana GW; Neumeyer JL; Law SJ
Eur J Pharmacol; 1980 Oct; 67(1):105-10. PubMed ID: 7418727
[TBL] [Abstract][Full Text] [Related]
3. On the ability of N-chloroethyl aporphine derivatives to cause irreversible inhibition of dopamine receptor mechanisms.
Costall B; Fortune DH; Granchelli FE; Law SJ; Naylor RJ; Neumeyer JL; Nohria V
J Pharm Pharmacol; 1980 Aug; 32(8):571-6. PubMed ID: 6106696
[No Abstract] [Full Text] [Related]
4. Aporphines, 36. Dopamine receptor interactions of trihydroxyaporphines. Synthesis, radioreceptor binding, and striatal adenylate cyclase stimulation of 2,10,11-trihydroxyaporphines in comparison with other hydroxylated aporphines.
Neumeyer JL; Arana GW; Law SJ; Lamont JS; Kula NS; Baldessarini RJ
J Med Chem; 1981 Dec; 24(12):1440-5. PubMed ID: 7310821
[TBL] [Abstract][Full Text] [Related]
5. The dopamine-sensitive adenylate cyclase of the rat caudate nucleus--3. The effect of aporphines and protoberberines.
Sheppard H; Brughardt CR
Biochem Pharmacol; 1978; 27(8):1113-6. PubMed ID: 697912
[No Abstract] [Full Text] [Related]
6. The effects of (-)N-(chloroethyl)-norapomorphine on [3H]-apomorphine binding to striatal dopamine receptors.
Goosey MW; Doggett NS
Biochem Pharmacol; 1982 Nov; 31(22):3693-4. PubMed ID: 7181954
[No Abstract] [Full Text] [Related]
7. Aporphines as antagonists of dopamine D-1 receptors.
Schaus JM; Titus RD; Foreman MM; Mason NR; Truex LL
J Med Chem; 1990 Feb; 33(2):600-7. PubMed ID: 2405158
[TBL] [Abstract][Full Text] [Related]
8. Motor inhibition induced by aporphine derivatives in the mouse.
Bradbury AJ; Costall B; Naylor RJ; Neumeyer JL
J Pharm Pharmacol; 1983 Aug; 35(8):494-9. PubMed ID: 6137533
[No Abstract] [Full Text] [Related]
9. Aporphines. 15. Action of aporphine alkaloids on dopaminergic mechanisms in rat brain.
Miller RJ; Kelly PH; Neumeyer JL
Eur J Pharmacol; 1976 Jan; 35(1):77-83. PubMed ID: 943290
[TBL] [Abstract][Full Text] [Related]
10. Preparation and pharmacological evaluation of enantiomers of certain nonoxygenated aporphines: (+)- and (-)-aporphine and (+)- and (-)-10-methylaporphine.
Cannon JG; Raghupathi R; Moe ST; Johnson AK; Long JP
J Med Chem; 1993 May; 36(10):1316-8. PubMed ID: 8098770
[TBL] [Abstract][Full Text] [Related]
11. Aporphines, 21. (1,2) Dopaminergic activity of aporphine and benzylisoquinoline derivatives. Synthesis of 8-hydroxyaporphines and 1-(hydroxybenzyl)-2-n-propyl-1,2,3,4-tetrahydroisoquinolines.
Costall B; Naylor RJ
J Med Chem; 1977 Feb; 20(2):190-6. PubMed ID: 556776
[TBL] [Abstract][Full Text] [Related]
12. Synthesis and dopamine agonist and antagonist effects of (R)-(-)- and (S)-(+)-11-hydroxy-N-n-propylnoraporphine.
Gao Y; Zong R; Campbell A; Kula NS; Baldessarini RJ; Neumeyer JL
J Med Chem; 1988 Jul; 31(7):1392-6. PubMed ID: 3385732
[TBL] [Abstract][Full Text] [Related]
13. Dopamine autoreceptors differ pharmacologically from postsynaptic dopamine receptors: effects of (-)-N-(2-chloroethyl)-norapomorphine.
Lehmann J; Langer SZ
Eur J Pharmacol; 1982 Jan; 77(1):85-6. PubMed ID: 7060630
[No Abstract] [Full Text] [Related]
14. Aporphines. 58. N-(2-chloroethyl) [8,9-2H]norapomorphine, an irreversible ligand for dopamine receptors: synthesis and application.
Guan JH; Neumeyer JL; Filer CN; Ahern DG; Lilly L; Watanabe M; Grigoriadis D; Seeman P
J Med Chem; 1984 Jun; 27(6):806-10. PubMed ID: 6737423
[TBL] [Abstract][Full Text] [Related]
15. Dissociation between behavioral effects of (-)-N-(2-chloroethyl)-norapomorphine and D2 dopamine receptor-like activity.
Helmeste DM
Eur J Pharmacol; 1983 Nov; 95(3-4):277-81. PubMed ID: 6317413
[TBL] [Abstract][Full Text] [Related]
16. Inhibition of dopamine-stimulated adenylate cyclase activity by phenoxybenzamine.
Walton KG; Liepmann P; Baldessarini RJ
Eur J Pharmacol; 1978 Nov; 52(2):231-4. PubMed ID: 729635
[TBL] [Abstract][Full Text] [Related]
17. Synthesis and dopamine receptor affinities of N-alkyl-11-hydroxy-2-methoxynoraporphines: N-alkyl substituents determine D1 versus D2 receptor selectivity.
Si YG; Gardner MP; Tarazi FI; Baldessarini RJ; Neumeyer JL
J Med Chem; 2008 Feb; 51(4):983-7. PubMed ID: 18251489
[TBL] [Abstract][Full Text] [Related]
18. Presynaptic inhibition of dopamine synthesis in rat striatal tissue by enantiomeric mono- and dihydroxyaporphines.
Booth RG; Baldessarini RJ; Kula NS; Gao Y; Zong R; Neumeyer JL
Mol Pharmacol; 1990 Jul; 38(1):92-101. PubMed ID: 1973525
[TBL] [Abstract][Full Text] [Related]
19. The binding of [3H]N-(chloroethyl)-norapomorphine to rat striatal membranes.
Kilpatrick GJ; Jenner P; Marsden CD
Eur J Pharmacol; 1984 Dec; 107(1):71-8. PubMed ID: 6084599
[TBL] [Abstract][Full Text] [Related]
20. Postsynaptic receptors are not essential for dopaminergic feedback regulation.
Di Chiara G; Porceddu ML; Fratta W; Gessa GL
Nature; 1977 May; 267(5608):270-2. PubMed ID: 865621
[No Abstract] [Full Text] [Related]
[Next] [New Search]
